Is it safe to buy these Stocks, Equity Residential (NYSE:EQR), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Equity Residential (NYSE:EQR):

On 14-05-2019 (Tuesday), Equity Residential (NYSE:EQR)’s price settled at $75.81 with the percent change of -0.04%. The company has its outstanding shares of 365.6 Million. A total of 806749 shares exchanged at hands and its Average Volume (3 months) is 1.32 Million. The company has a market cap of $27.73 Billion.

The highest price of EQR touched in the last 12 month was $77.69 and the lowest price it hit in the same period was $59.29. Stock’s distance from 52 week High is -2.42% and the distance from 52 week Low is 27.86%.

Performance Overview of Equity Residential (NYSE:EQR)

Equity Residential (NYSE:EQR) currently shows its YTD (Year to Date) performance of 14.89 percent, whereas its Weekly performance stands at -0.49%. The Monthly and Yearly performances are -1.11 percent and 20.55 percent respectively.

Earnings and Revenue Snapshot of Equity Residential (NYSE:EQR)

Equity Residential (NYSE:EQR)’s Average Earnings Estimate for the Current Fiscal quarter is $0.85, according to consensus of 23 analysts. They are also projecting the Low EPS estimate of $0.8 and the High EPS estimate of $0.88.

The company’s Average Revenue Estimate for the current quarter is $666.05 Million, while Low and High Revenue Estimates are $660.11 Million and $676.6 Million respectively. These Revenue projections are a consensus of 15 Analysts.

Price Insight of Equity Residential (NYSE:EQR)

Price target given by certain analysts help investors in deciding about buying, selling or holding a stock. Analyst’s mean target price for the company is $74.85. The SMA20 for the stock is at 0.24 percent, SMA50 stands at 0.82 percent, while SMA200 is 8.51 Percent, according to Finviz reported data.

Return on Assets (ROA) value of the stock is 2.7 Percent. The Return on Equity (ROE) and Return on Investment (ROI) values are 5.4 percent and 4.5 percent respectively. Equity Residential (NYSE:EQR) has an average true range (ATR) of 1.19

Profitability and Ratings Review of Equity Residential (NYSE:EQR)

Equity Residential (NYSE:EQR)’s profitability analysis greatly helps in making investment decision. Net profit margin of Equity Residential was recorded at 21 percent, operating profit margin was 33.4 percent, while gross profit margin stands at 65.9 percent. Beta factor was calculated at 0.63. Relative Strength Index (RSI) for EQR is at 51.77.

Equity Residential (NYSE:EQR) was covered by a number of analysts recently, 2 rated the stock as Buy, 2 rated Outperform, 17 rated Hold, 2 gave an Underperform and 0 rated sell.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) ended its previous trading session at $54.85 with the gain of 12.79% on 14-05-2019 (Tuesday). The market capitalization of the company is $2.38 Billion. Overall, 1.11 Million shares exchanged hands versus its average volume of $483.66 Million. Arena Pharmaceuticals, Inc. is 1.89% below its 1-Year High which is $55. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has a difference of 71.57% from its 1 year low which stands at $31.97.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Analysts Coverage

Looking at Recommendation Trends of the stock polled by Reuters. For the Current month, 4 analysts have assigned this stock as Buy where 5 assigned Outperform, 1 analysts believe it’s a Hold, 0 said Underperform and only 0 assigned Sell rating.

Revenue and Earnings Outlook of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

According to 7 analysts, the Average Revenue Estimate is $3.97 Million for the current Fiscal quarter. The Low Revenue estimate is $2 Million, while High Revenue estimate is $6 Million.

For the current Fiscal Quarter, 6 analysts on average are expecting earnings of $-0.98 per share. According to the Analysts, the Low Estimate Earnings of the current Quarter is $-1.14 whereas, High Estimate is $-0.77

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Performance and Ratio Review

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) performance during the last one year upgraded 12.75 percent, while its year to date (YTD) performance showed a positive trend of 24.85 percent. The stock optimistic 0.72 percent over the past 1 month. Its weekly performance showed downward trend of -1.32 percent.

The Price to Sales (P/S) of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is 2.92, while P/B (Price to Book) stands at 3.97. The company P/E (price to earnings) ratio is 4 and Forward P/E ratio is 0, while its P/C (price to Cash) ratio stands at 5.35.

Technical Indicators of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Arena Pharmaceuticals, Inc.’s RSI (Relative strength index) is at 67.43, its ATR (Average True Range) value is 2.15, while its Beta factor was calculated at 1.68. ARNA has been given an analysts’ mean target of 67.1.